Staff switches at FDA's device center
This article was originally published in The Silver Sheet
Executive Summary
CDRH has experienced a heavy dose of staff reorganization this year, with more than 40 upper-level moves since January. The Office of Device Evaluation (ODE) in June brought in Ginette Michaud from its division of anesthesiology, general hospital, infection control and dental devices to serve as acting clinical deputy director. Michaud replaces Aron Yustein, on detail to the Office of Surveillance and Biometrics (OSB) since February. Former Division of Enforcement B deputy director Christy Foreman is the new acting deputy director for science and review policy at ODE, and Barbara Zimmerman is the ODE acting associate director, replacing Robert Gatling. Gatling will permanently head up the ODE program operations staff, which freed Heather Rosecrans to return to her post as director of the 510(k) section. Meanwhile, former Office of Compliance staffer Nicole Wolanski replaced Samie Allen in May as PMA section director. And in mid-June, Ashley Boam left ODE's central office to return to her spot as chief of the interventional cardiology devices branch within the Division of Cardiovascular Devices. Further, the cardiovascular division named Mitchell Shein acting chief of the pacing, defibrillator and leads branch, after Megan Moynahan left in January to lead the Cardiac Electrophysiology and Monitoring Network in the Office of the Center Director
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.